Talk:Richard Smeyne

Proposed expansion and update of Richard Smeyne biography

Conflict-of-interest disclosure: I am Richard Smeyne, the subject of this article. Because I have a conflict of interest, I am not making these substantive changes directly to the article. I am requesting that an uninvolved Wikipedia editor review the proposed revisions below and incorporate those that meet Wikipedia's sourcing, neutrality, biographical and notability standards. The current article provides a useful overview of my career but gives limited coverage of several major areas of research and contains some information that is now outdated. I am proposing a revised version that retains the basic biographical information while expanding and reorganizing the scientific content. The principal proposed changes are: • Expand the education and training section to include undergraduate education, graduate study, PhD training and postdoctoral training. • Separate career history from research contributions. • Expand the discussion of early transgenic research, particularly the development of the fos-lacZ transgenic mouse. The proposed text attributes to the Aligning Science Across Parkinson's Collaborative Research Network its description of this model as the first inducible transgenic mouse in which a cellular marker followed the expression pattern directed by its cognate gene promoter. The original 1992 Neuron paper is also cited. • Add a separate section describing work on TrkA, TrkB and TrkC neurotrophin receptor signaling. • Reorganize the Parkinson's disease research into four areas: genetic and environmental susceptibility, exercise and neuroprotection, viral infection and multi-hit models, and peripheral immunity/LRRK2. • Add sourced information concerning awards and honors. • Add a concise section on scientific leadership, peer review and editorial service. • Correct outdated information concerning leadership of the Parkinson's Foundation Scientific Advisory Board. • Remove the fixed publication count and ranking language, which can become outdated and is not central to the biography. • Retain language identifying findings from animal studies as experimental results rather than implying that they establish causation in human Parkinson's disease. Most scientific statements are supported directly by peer-reviewed publications. Institutional and professional sources are used primarily for appointments, awards and organizational service. Several older honors and service activities for which I have not identified a suitable public source are marked with so that an editor can decide whether they should be retained. Proposed replacement article text:

Richard Jay Smeyne
Alma mater	Saint Joseph's University (BS)Thomas Jefferson University (PhD)
Known for	Transgenic models of neuronal activity; neurotrophin receptor signaling; experimental Parkinson's disease; neuroimmune mechanisms of neurodegeneration
Scientific career
Fields	Neuroscience, neurobiology, Parkinson's disease
Workplaces	Thomas Jefferson UniversitySt. Jude Children's Research HospitalHoffmann-La RocheBristol Myers SquibbRoche Institute of Molecular Biology
Academic advisors	James I. MorganTom Curran

Richard Jay Smeyne is an American neuroscientist whose research has focused on transgenic models of nervous-system function, neurotrophin signaling, and the genetic, environmental and immune mechanisms underlying Parkinson's disease. He is professor and chair of the Department of Neuroscience at Thomas Jefferson University and director of the Jefferson Comprehensive Parkinson's Center at the Vickie and Jack Farber Institute for Neuroscience."Faculty & Staff – Department of Neuroscience". Thomas Jefferson University. Retrieved September 10, 2026."Smeyne Research – Team". Thomas Jefferson University. Retrieved September 10, 2026.

Education and training

Smeyne studied biology at Saint Joseph's University in Philadelphia and subsequently undertook graduate study in experimental psychology at the University of Hartford."Episode 35: Preclinical Models of PD". Parkinson's Foundation. August 14, 2018. Retrieved September 10, 2026. He received his PhD from Thomas Jefferson University in 1989, where his work focused on neuroanatomy and nervous-system development. From 1989 to 1992, Smeyne was a postdoctoral fellow at the Roche Institute of Molecular Biology in Nutley, New Jersey, working with James I. Morgan and Tom Curran. There he studied regulation of the immediate-early gene c-fos and developed transgenic approaches for identifying activated neuronal populations.Smeyne, Richard J.; Schilling, Karl; Robertson, Linda; Luk, David; Oberdick, John; Curran, Tom; Morgan, James I. (1992). "fos-lacZ transgenic mice: mapping sites of gene induction in the central nervous system". Neuron. 8 (1): 13–23. doi:10.1016/0896-6273(92)90105-M. PMID 1730004.

Career

Smeyne joined the Bristol-Myers Squibb Pharmaceutical Research Institute in 1992, where he worked with Mariano Barbacid and colleagues on genetically modified mice carrying alterations in Trk-family neurotrophin receptors. In 1994, he joined Hoffmann-La Roche and headed its Neurogenetics Program in the Division of Central Nervous System Research. In 1996, Smeyne moved to St. Jude Children's Research Hospital, where he developed a research program increasingly focused on Parkinson's disease, including genetic susceptibility, environmental exposures, oxidative stress, exercise and viral infection. He returned to Thomas Jefferson University in 2016 as professor of neuroscience and director of the Jefferson Comprehensive Parkinson's Disease and Movement Disorder Center. The center was designated a Parkinson's Foundation Center of Excellence in 2019."Jefferson Named One of Three New Centers of Excellence in Parkinson's Care". Thomas Jefferson University. August 6, 2019. Retrieved September 10, 2026. Smeyne became chair of Jefferson's Department of Neuroscience in 2022.

Research

Transgenesis and neuronal gene expression

During his postdoctoral work, Smeyne and colleagues developed transgenic approaches for studying gene expression in specific neuronal populations. Early studies used neuronal promoters to regulate reporter genes in the developing cerebellum.Oberdick, John; Smeyne, Richard J.; Mann, James R.; Zackson, Susan; Morgan, James I. (1990). "A promoter that drives transgene expression in cerebellar Purkinje and retinal bipolar neurons". Science. 248: 223–226. PMID 2109351. Smeyne and colleagues subsequently developed the fos-lacZ transgenic mouse, in which bacterial beta-galactosidase served as a cellular reporter controlled by regulatory sequences from the endogenous c-fos gene. The reporter faithfully reproduced both constitutive and stimulus-induced patterns of c-fos expression, allowing individual populations of activated cells to be identified histologically.Smeyne, Richard J.; Schilling, Karl; Robertson, Linda; Luk, David; Oberdick, John; Curran, Tom; Morgan, James I. (1992). "fos-lacZ transgenic mice: mapping sites of gene induction in the central nervous system". Neuron. 8 (1): 13–23. doi:10.1016/0896-6273(92)90105-M. PMID 1730004. The Aligning Science Across Parkinson's Collaborative Research Network has described the fos-lacZ model as the first inducible transgenic mouse in which expression of a cellular marker followed the expression pattern directed by its cognate gene promoter."Richard Smeyne". Aligning Science Across Parkinson's Collaborative Research Network. Retrieved September 10, 2026. The model therefore provided an early genetic method for translating the activation of an endogenous cellular gene into an easily visualized reporter signal and enabled neuronal activity mapping at cellular resolution. The fos-lacZ mouse was subsequently used to examine developmental patterns of gene activation in the nervous system.Smeyne, Richard J.; Curran, Tom; Morgan, James I. (1992). "Temporal and spatial expression of a fos-lacZ transgene in the developing nervous system". Molecular Brain Research. 16 (1–2): 158–162. PMID 1334194. In a 1993 study in Nature, Smeyne and colleagues used this approach to show that sustained c-fos expression preceded naturally occurring programmed cell death in several developing tissues.Smeyne, Richard J.; Vendrell, Montserrat; Hayward, Michael; Baker, Suzanne J.; Miao, Graham G.; Schilling, Karl; Robertson, Linda M.; Curran, Tom; Morgan, James I. (1993). "Continuous c-fos expression precedes programmed cell death in vivo". Nature. 363: 166–169. doi:10.1038/363166a0. PMID 8483500.

Neurotrophin receptor signaling

At Bristol-Myers Squibb, Smeyne worked with Mariano Barbacid and colleagues to define the physiological functions of Trk-family neurotrophin receptors. Targeted disruption of trkB, a receptor for brain-derived neurotrophic factor, produced abnormalities in the central and peripheral nervous systems and neonatal death, demonstrating an essential role for TrkB signaling during nervous-system development.Klein, Rüdiger; Smeyne, Richard J.; Wurst, Wolfgang; Long, Linda K.; Auerbach, B. Anna; Joyner, Alexandra L.; Barbacid, Mariano (1993). "Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death". Cell. 75 (1): 113–122. PMID 8402890. Smeyne was first author of a 1994 Nature study showing that disruption of trk, encoding the high-affinity nerve growth factor receptor TrkA, produced severe sensory and sympathetic neuropathies and loss of peripheral neurons.Smeyne, Richard J.; Klein, Rüdiger; Schnapp, Andreas; Long, Linda K.; Bryant, Sherri; Lewin, Anne; Lira, Sergio A.; Barbacid, Mariano (1994). "Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene". Nature. 368 (6468): 246–249. doi:10.1038/368246a0. PMID 8145823. Related work on trkC showed that mice lacking functional TrkC receptors lost Ia muscle afferent projections and developed abnormalities of movement and posture, establishing a role for NT-3/TrkC signaling in proprioceptive sensory pathways.Klein, Rüdiger; Silos-Santiago, Inmaculada; Smeyne, Richard J.; Lira, Sergio A.; Brambilla, Riccardo; Bryant, Sherri; Zhang, Li; Snider, William D.; Barbacid, Mariano (1994). "Disruption of the neurotrophin-3 receptor gene trkC eliminates Ia muscle afferents and results in abnormal movements". Nature. 368 (6468): 249–251. doi:10.1038/368249a0. PMID 8145824.

Parkinson's disease

Smeyne's later research has focused on factors determining vulnerability and resilience of dopaminergic neurons in the substantia nigra pars compacta. His work has examined interactions among genetics, environmental exposures, infection, oxidative stress, exercise and peripheral immune signaling.

Genetic and environmental susceptibility

Beginning in the late 1990s, Smeyne's laboratory used genetically distinct mouse strains to study variation in susceptibility to the dopaminergic neurotoxin MPTP. The work demonstrated substantial strain-dependent differences in neuronal loss and was used to identify genetic and cellular determinants of experimental parkinsonism.Hamre, Kristin; Tharp, Robert; Poon, Kim; Xiong, Xiaoping; Smeyne, Richard J. (1999). "Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration acts in an autosomal dominant fashion". Brain Research. 828: 91–103. PMID 10320728. Subsequent genetic mapping identified a quantitative trait locus associated with susceptibility to MPTP-induced substantia nigra neuron loss.Cook, R.; Lu, L.; Gu, J.; Williams, R. W.; Smeyne, R. J. (2003). "Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice". Molecular Brain Research. 110: 279–288. PMID 12591164.

Exercise and neuroprotection

Smeyne and colleagues reported that environmental enrichment and voluntary exercise protected dopaminergic neurons against MPTP-induced injury in mice.Faherty, Christina J.; Shepherd, Kennie R.; Herasimtschuk, Anna; Smeyne, Richard J. (2005). "Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism". Molecular Brain Research. 134 (1): 170–179. doi:10.1016/j.molbrainres.2004.08.008. PMID 15790541.Gerecke, Kim M.; Jiao, Yun; Pani, A.; Pagala, V.; Smeyne, Richard J. (2010). "Exercise protects against MPTP-induced neurotoxicity in mice". Brain Research. 1341: 72–83. doi:10.1016/j.brainres.2010.01.053. PMID 20116369. Later studies implicated brain-derived neurotrophic factor and HIF-1α in exercise-induced neuroprotection.Gerecke, Kim M.; Jiao, Yun; Pagala, Viswajeeth; Smeyne, Richard J. (2012). "Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice". PLOS One. 7 (8): e43250. doi:10.1371/journal.pone.0043250. PMID 22912838.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)Smeyne, Michelle; Sladen, Paul; Jiao, Yun; Dragatsis, Ioannis; Smeyne, Richard J. (2015). "HIF1alpha is necessary for exercise-induced neuroprotection while HIF2alpha is needed for dopaminergic neuron survival in the substantia nigra pars compacta". Neuroscience. 295: 23–38. doi:10.1016/j.neuroscience.2015.03.015. PMID 25796140. His group has continued to investigate neurotrophic, metabolic, vascular and inflammatory mechanisms associated with exercise in Parkinson's disease.Rodriguez, Tabitha N.; Smeyne, Richard J.; Smeyne, Michelle (2026). "Neurobiology of exercise in Parkinson's disease". Journal of Parkinson's Disease. doi:10.1177/1877718X261452869. PMID 42159410.

Viral infection and multi-hit models

Smeyne's laboratory has investigated whether viral infection and immune activation can alter long-term vulnerability of the nigrostriatal system. In 2009, Smeyne and colleagues reported that highly pathogenic H5N1 influenza virus entered the central nervous system of mice and was followed by persistent microglial activation, changes in alpha-synuclein and delayed dopaminergic neuron loss.Jang, Haeman; Boltz, David; Sturm-Ramirez, Katharine; Shepherd, Kennie R.; Jiao, Yun; Webster, Robert; Smeyne, Richard J. (2009). "Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration". Proceedings of the National Academy of Sciences of the United States of America. 106 (33): 14063–14068. doi:10.1073/pnas.0900096106. PMID 19667183. The group later showed that non-neurotropic H1N1 influenza produced prolonged microglial activation and increased susceptibility to a later subthreshold MPTP challenge. Influenza vaccination or antiviral treatment prevented this interaction in the experimental model, supporting a multi-hit model of Parkinson's disease susceptibility.Sadasivan, Shankar; Zanin, Mark; O'Brien, Katie; Schultz-Cherry, Stacey; Smeyne, Richard J. (2015). "Induction of microglia activation after infection with the non-neurotropic A/CA/04/2009 H1N1 influenza virus". PLOS One. 10 (4): e0124047. PMID 25861024.Sadasivan, Shankar; Sharp, Bridgett; Schultz-Cherry, Stacey; Smeyne, Richard J. (2017). "Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis". npj Parkinson's Disease. 3: 18. doi:10.1038/s41531-017-0019-z. PMID 28649618.{{cite journal}}: CS1 maint: unflagged free DOI (link) A 2022 study similarly found that mice recovering from experimental SARS-CoV-2 infection showed increased neuroinflammation and dopaminergic neuron loss after subsequent exposure to an otherwise non-lesioning dose of MPTP.Smeyne, Richard J.; Eells, Jeffrey B.; Chatterjee, Debotri; Byrne, Matthew; Akula, Shaw M.; Sriramula, Srinivas; O'Rourke, Dorcas P.; Schmidt, Peter (2022). "COVID-19 infection enhances susceptibility to oxidative stress-induced parkinsonism". Movement Disorders. 37 (7): 1394–1404. doi:10.1002/mds.29116. PMID 35579496.

Peripheral immunity and LRRK2

Smeyne's laboratory has also investigated interactions between systemic immune signaling and pathogenic variants of LRRK2. A 2018 study in Brain found that mice carrying pathogenic LRRK2 mutations developed enhanced peripheral and central inflammatory responses and long-term dopaminergic neuron loss after systemic inflammatory stimulation.Kozina, Elena; Sadasivan, Shankar; Jiao, Yun; Dou, Yuchen; Ma, Zhijun; Tan, Haiyan; Kodali, Kiran; Shaw, Timothy; Peng, Junmin; Smeyne, Richard J. (2018). "Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo". Brain. 141 (6): 1753–1769. doi:10.1093/brain/awy077. PMID 29800472. In 2022, Smeyne and colleagues used chimeric mouse models to separate LRRK2 genotype in peripheral immune cells from that in the central nervous system. Replacing mutant LRRK2-expressing immune cells with wild-type cells prevented dopaminergic neuronal loss, while pathogenic LRRK2 expression in peripheral lymphocytes increased neuronal vulnerability. Neutralization of circulating IL-6 also prevented neuronal loss.Kozina, Elena; Byrne, Matthew; Smeyne, Richard J. (2022). "Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease". npj Parkinson's Disease. 8: 24. doi:10.1038/s41531-022-00289-9. PMID 35292674.{{cite journal}}: CS1 maint: unflagged free DOI (link) These findings supported a model in which dysregulated peripheral immune responses can contribute to neurodegeneration in genetically susceptible forms of Parkinson's disease.

Awards and honors

Smeyne received a Sigma Xi Research Award while a doctoral student at Thomas Jefferson University in 1985. He was a Rothschild Fellow at the Roche Institute of Molecular Biology from 1990 to 1992. According to the Aligning Science Across Parkinson's Collaborative Research Network, Smeyne was the first recipient of the Parkinson's Foundation Impact Award. He was also listed among the Foundation's 2018 Impact Award recipients."Parkinson's Foundation Increases Funding to $6.2 Million to Advance Parkinson's Research". Parkinson's Foundation. 2018. Retrieved September 10, 2026. In 2019, Smeyne received the Excellence in Medical Research Award at The Philadelphia Inquirer Influencers of Healthcare awards."Seven Jefferson Healthcare Leaders Honored by the Philadelphia Inquirer". Thomas Jefferson University. August 30, 2019. Retrieved September 10, 2026. In 2025, Jefferson Research announced that Smeyne received a Springer Nature Editor's Choice Award for his editorial work with npj Parkinson's Disease."Congratulations to Dr. Richard Smeyne on receiving the Editor's Choice Award from Springer Nature". LinkedIn. Jefferson Research. 2025. Retrieved September 10, 2026.

Scientific leadership and service

Smeyne has served on scientific review panels for the National Institutes of Health, Parkinson's disease foundations and other research organizations. He served for approximately 25 years in scientific advisory and grant-review roles for the Parkinson's Foundation, including service as chair of its Scientific Advisory Board. A 2022 publication identified him as chair of the board at that time.Smeyne, Richard J.; Eells, Jeffrey B.; Chatterjee, Debotri; Byrne, Matthew (2022). "COVID-19 infection enhances susceptibility to oxidative stress-induced parkinsonism". Movement Disorders. 37 (7): 1394–1404. doi:10.1002/mds.29116. He has also chaired peer-review panels for Parkinson's disease research sponsored by the United States Department of Defense and the NIH. His editorial service has included Molecular Brain Research, Developmental Brain Research, Brain Research, PLOS ONE and npj Parkinson's Disease. At the 2026 World Parkinson Congress in Phoenix, Smeyne delivered a plenary presentation on the neurobiology of exercise in Parkinson's disease."Faculty". World Parkinson Congress. Retrieved September 10, 2026.

Selected publications

• Smeyne, Richard J.; Schilling, Karl; Robertson, Linda; Luk, David; Oberdick, John; Curran, Tom; Morgan, James I. (1992). "fos-lacZ transgenic mice: mapping sites of gene induction in the central nervous system". Neuron. 8 (1): 13–23. doi:10.1016/0896-6273(92)90105-M. PMID 1730004. • Smeyne, Richard J.; Vendrell, Montserrat; Hayward, Michael; Baker, Suzanne J.; Miao, Graham G.; Schilling, Karl; Robertson, Linda M.; Curran, Tom; Morgan, James I. (1993). "Continuous c-fos expression precedes programmed cell death in vivo". Nature. 363: 166–169. doi:10.1038/363166a0. • Smeyne, Richard J.; Klein, Rüdiger; Schnapp, Andreas; Long, Linda K.; Bryant, Sherri; Lewin, Anne; Lira, Sergio A.; Barbacid, Mariano (1994). "Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene". Nature. 368: 246–249. doi:10.1038/368246a0. • Jang, Haeman; Boltz, David; Sturm-Ramirez, Katharine; Shepherd, Kennie R.; Jiao, Yun; Webster, Robert; Smeyne, Richard J. (2009). "Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration". Proceedings of the National Academy of Sciences of the United States of America. 106 (33): 14063–14068. doi:10.1073/pnas.0900096106. • Kozina, Elena; Sadasivan, Shankar; Jiao, Yun; Dou, Yuchen; Ma, Zhijun; Tan, Haiyan; Kodali, Kiran; Shaw, Timothy; Peng, Junmin; Smeyne, Richard J. (2018). "Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo". Brain. 141 (6): 1753–1769. doi:10.1093/brain/awy077. • Kozina, Elena; Byrne, Matthew; Smeyne, Richard J. (2022). "Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease". npj Parkinson's Disease. 8: 24. doi:10.1038/s41531-022-00289-9.{{cite journal}}: CS1 maint: unflagged free DOI (link) • Smeyne, Richard J.; Eells, Jeffrey B.; Chatterjee, Debotri; Byrne, Matthew (2022). "COVID-19 infection enhances susceptibility to oxidative stress-induced parkinsonism". Movement Disorders. 37 (7): 1394–1404. doi:10.1002/mds.29116.

References

References

External links

• Smeyne Laboratory, Thomas Jefferson University • of Neuroscience, Thomas Jefferson University • Richard Smeyne profile, Aligning Science Across Parkinson's Collaborative Research Network ection. In particular, if an editor believes some of the primary research papers should be supplemented or replaced by independent secondary sources, I would welcome that change. My goal is to provide accurate source material for independent editorial review rather than to dictate the final wording of the article. Thank you for reviewing this request. The current live article still contains the older compact biography, including the outdated statement that Smeyne “currently” chairs the Parkinson’s Foundation Scientific Advisory Board, so explicitly identifying that correction in the request is useful. (Wikipedia) . — Preceding unsigned comment added by Richardsmeyne (talk • contribs)